BOSTON, SAN DIEGO, SAN FRANCISCO and SEATTLE, May 14 /PRNewswire/ -- Paul A. Grayson and John Mendlein have joined Fate Therapeutics as president and CEO and executive chairman, respectively.

By Angel Gonzalez, Seattle Times Nov. 30--A group of venture capitalists is investing $12 million to launch Fate Therapeutics, a biotech company aiming to develop drugs that spur dormant adult stem cells to regenerate damaged tissue.

A group of the nation's most respected leaders in stem cell biology today announced formation of Fate Therapeutics, a new biotechnology company developing drugs to control cell fate.